CancerTYPE ID in the Clinic

Ralph V. Boccia, MD, FACP

Video Categories: PMO Interview with the Innovator Series: Volume 9

Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice.
August 15, 2013

Personalizing Therapy for Patients With CML

Dr. Mauro addresses the debate over selecting first line therapy with three approved agents available.

November 10, 2012

PMO Interview with the Innovator Series: Volume 2

The publishers of Personalized Medicine in Oncology (PMO) invite you to watch an interview with Peter Hirth, PhD, Chief Executive Officer of Plexxikon. In part one, Dr. Hirth discusses the use of biomarkers, segmenting the population of melanoma patients into subsets, and other aspects of personalized medicine.